NCT04002180View on ClinicalTrials.gov

Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Crohn's Disease]

Active, not recruitingOBSERVATIONAL
Enrollment

335

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Crohn's Disease
Interventions
DRUG

Vedolizumab (Genetical Recombination)

Vedolizumab IV infusion

Trial Locations (1)

Unknown

Takeda Selected Site, Tokyo

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT04002180 - Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Crohn's Disease] | Biotech Hunter | Biotech Hunter